Want to see HK:2617 full AI Analyst Report?
TransThera Sciences (Nanjing). Inc. (2617) Stock Statistics & Valuation Metrics
Total Valuation
TransThera Sciences (Nanjing). Inc. has a market cap or net worth of HKD 2.63B. The enterprise value is HKD 3.65B.
- Market Cap
- HKD 2.63B
- Enterprise Value
- HKD 3.65B
Share Statistics
TransThera Sciences (Nanjing). Inc. has 313,347,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 313,347,700
- Owned by Insiders
- ―
- Owned by Institutions
- 0.03%
Financial Efficiency
TransThera Sciences (Nanjing). Inc.’s return on equity (ROE) is -0.71 and return on invested capital (ROIC) is -71.81%.
- Return on Equity (ROE)
- -0.71
- Return on Assets (ROA)
- -0.54
- Return on Invested Capital (ROIC)
- -71.81%
- Return on Capital Employed (ROCE)
- -0.72
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.24M
- Employee Count
- 132
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of TransThera Sciences (Nanjing). Inc. is -6.91. TransThera Sciences (Nanjing). Inc.’s PEG ratio is 0.24.
- PE Ratio
- -6.91
- PS Ratio
- 80.74
- PB Ratio
- 3.25
- Price to FCF
- -19.53
- Price to Operating Cash Flow
- -19.77
- PEG Ratio
- 0.24
Income Statement
In the last 12 months, TransThera Sciences (Nanjing). Inc. had revenue of 0 and earned -295.96M in profits. Earnings per share was -0.76.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -300.18M
- Pretax Income
- -295.96M
- Net Income
- -295.96M
- EBITDA
- -290.82M
- Earnings Per Share (EPS)
- -0.76
Cash Flow
In the last 12 months, operating cash flow was -144.47M and capital expenditures -78,330, giving a free cash flow of -144.55M billion.
- Operating Cash Flow
- -144.47M
- Free Cash Flow
- -144.55M
- Free Cash Flow per Share
- -0.36
Dividends & Yields
TransThera Sciences (Nanjing). Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -5.12%
- Earnings Yield
- -9.39%
Stock Price Statistics
- Beta
- 2.97
- 52-Week Price Change
- -95.16%
- 50-Day Moving Average
- 9.82
- 200-Day Moving Average
- 36.74
- Relative Strength Index (RSI)
- 34.35
- Average Volume (3m)
- 7.03M
Important Dates
TransThera Sciences (Nanjing). Inc. upcoming earnings date is ―, Before Open (Confirmed).
- Last Earnings Date
- Aug 26, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
TransThera Sciences (Nanjing). Inc. as a current ratio of 3.87, with Debt / Equity ratio of 0.40%
- Current Ratio
- 3.87
- Quick Ratio
- 3.87
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.42
- Interest Coverage Ratio
- -2480.84
Taxes
In the past 12 months, TransThera Sciences (Nanjing). Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
TransThera Sciences (Nanjing). Inc. EV to EBITDA ratio is -8.98, with an EV/FCF ratio of -16.63.
- EV to Sales
- 68.74
- EV to EBITDA
- -8.98
- EV to Free Cash Flow
- -16.63
- EV to Operating Cash Flow
- -16.64
Balance Sheet
TransThera Sciences (Nanjing). Inc. has HKD 925.22M in cash and marketable securities with HKD 5.61M in debt, giving a net cash position of HKD 919.61M billion.
- Cash & Marketable Securities
- HKD 925.22M
- Total Debt
- HKD 5.61M
- Net Cash
- HKD 919.61M
- Net Cash Per Share
- HKD 2.93
- Tangible Book Value Per Share
- HKD 2.19
Margins
Gross margin is 87.74%, with operating margin of -1133.21%, and net profit margin of -767.30%.
- Gross Margin
- 87.74%
- Operating Margin
- -1133.21%
- Pretax Margin
- -1115.32%
- Net Profit Margin
- -767.30%
- EBITDA Margin
- -765.29%
- EBIT Margin
- -777.69%
Analyst Forecast
The average price target for TransThera Sciences (Nanjing). Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -13.19%
Scores
- Smart Score
- 1
- AI Score
- 45